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The subclinical and low intensity inflammation, oxidative stress, high calorie and high fat diet patterns are 
striking features of the obesity. The adipose tissue, through its endocrine function, is associated with the 
cytokines secretion, such as: IL-4, IL-13, IL-15 and IFN-γ, which trigger metabolic changes and possibly 
modulate the energy metabolism by modifying the biochemical, anthropometric and body composition 
parameters. This review summarizes scientific evidences about the relationship between such cytokines and 
mediators which alter the energy metabolism, predisposing or preventing the obesity. 
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Introduction 
The obesity, a disease with a complex and multifactorial 
etiology 
[1, 2]
, is associated with an imbalance in the energy
balance, the altered oxidative status 
[3, 4]
 and the subclinical
and low intensity systemic inflammation 
[3-7]
.
Such metabolic changes stimulate the white adipose tissue 
(WAT) to secrete cytokines, for example, interleukin 4 
(IL-4 ), interleukin 13 (IL-13), interleukin 15 (IL-15) and 
IFN-γ (interferon-gamma), or other inflammatory markers 
which could modulate the energy metabolism and, 
consequently, modify anthropometric, biochemical and body 
composition parameters 
[5]
. However, so far, it is not known
the exactly role, as well as the magnitude of the effect that 
each one of these mediators can have on the predisposition or 
prevention of obesity. 
It has been shown that during obesity, elevated 
concentrations of IFN-γ favor the body weight gain and 
impair the glucose homeostasis 
[8-10]
. However, the
suppression of this mediator promotes inverse effect. It 
favors the body weight reduction and improves of insulin 
sensitivity, since the absence of such mediator promotes the 
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decreased food intake, suppressing the orexigenic and 
stimulating the anorexigenic route
[8]
. So, it is plausible to
infer that there is correlation between such mediator and 
mechanisms which alter the energy metabolism. 
In other hand, the IL-4, IL-13 and IL-15 with a 
predominantly anti-inflammatory effect on WAT, can 
modulate the energy metabolism by increasing insulin 
sensitivity and reducing the body weight and fat which 
contributes to the obesity prevention 
[6, 11-14]
.
Given the importance of the subject and the scarcity in 
literature about the modulation of inflammatory mediators 
that interfere with energy metabolism, this review aims to 
summarize studies that analyzed such mediators on the 
energy metabolism, focusing on IL-4, IL-13, IL-15 and 
IFN-γ biomarkers.  
Obesity, energy metabolism and inflammation 
Food intake is regulated in the hypothalamus, primarily by 
two large groups of neuropeptides: the anorexigenic, 
Melanocyte-stimulating hormone - Pro-opiomelanocortin 
(POMC) and amphetamine-regulated transcript (CART); the 
other group is the orexigenic: Neuropeptide Y (NPY) and 
Agouti-related peptide (AgRP) 
[15, 16]
. In the presence of the
Figure 1. Endocrine effect of the adipose tissue and signaling pathways of the oxidative stress and inflammatory response in obesity. The food 
intake, regulated by the hypothalamus, increases in obesity due to a higher stimulation of the orexigenic pathway. Thus, there is an imbalance in energy 
metabolism which favors the increase of plasma free fatty acids, as well as hypertrophy and hyperplasia of the adipocytes in the white adipose tissue 
and hypoxia, which are causes of oxidative state imbalance. This predisposes lower antioxidant (AOX) and higher ROS concentrations, as well as the 
greater cytokines expression through STAT and NF-Kβ pathways activation which features a subclinical and low intensity inflammation typical of 
obesity. 
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obesity, through the resistance to leptin, the anorexigenic 
neuropeptides do not perform their normal functions while the 
orexigenic become active, favoring the food intake increase 
[17]
. This consequently promotes metabolic changes, such as:




Thus, the typical standard diet in obesity consists of high 
calorie and fat consumption and low intake of antioxidant 
nutrients 
[6, 18, 19]
 which promote an increase in free fatty
acids plasma concentrations. Therefore, in the WAT, 
mitochondria do not perform their normal functions, getting 
overloaded and resulting in incomplete β-oxidation of fatty 
acids. This predisposes the homeostasis loss and increases 
the reactive oxygen species (ROS) production, triggering 
oxidative stress status. These changes lead to cells 
deterioration, resulting in insulin resistance or in a greater 
lipid accumulation in adipocytes, due to the increased 
nicotinamide adenine dinucleotide phosphate- reduced 




Hypoxia, from adiposity excess significantly alter the 
adipocytes vital parameters, such as: the increase in ROS 
(432.53%), lipids and proteins oxidation (376.6% and 
566.6%, respectively), the antioxidant enzymes and 
inflammatory mediators release reduction 
[21]
.
Thus, the adiposity excess and oxidative stress observed in 
obesity trigger an inflammatory cascade by phosphorylation 
of signal transduction and activation of transcription (STAT) 
pathways - Jun N-terminal kinase proteins (JNK); Nuclear 
Factor kappa Beta (NF-KB) 
[22]
. They are stimulated by the
macrophages influx in adipocytes, inducing the inflammatory 
cytokines synthesis that characterizes a low intensity and 
subclinical inflammatory process.  Such process is derived 
of the hypoxia in adipose tissue, adipocytes hypertrophy and 




According to Xu et al. 
[23]
 in obesity, some cytokines can
activate STAT3 gene that binds to the enhancer binding 
protein (C/EBP) gene target, promoting the adipogenesis. In 
this way, cytokines may regulate lipid metabolism through 
STAT pathway activation and play a promoter role to obesity 
[23, 24]
. In a Barbarroja et al. 
[25]
 study, obese individuals had
significantly higher STAT3 levels in comparison with lean 
controls, which links strongly the STAT3 to obesity (Figure 
1). 
On the other hand, there are evidences that the 
inflammatory response occurs to mobilization of energy 
reserves and anti-inflammatory cytokines in adipose tissue, 
such as: IL-4, IL-13 and IL-15, which elicit positive effects 
on metabolic homeostasis in nutrient overload situation. 
Moreover, they contribute to inhibition of pro-inflammatory 
cytokines expression and, consequently, reduce the 
inflammatory process in adipose tissue. So, these interleukins 
action is essential to modulate energy metabolism should be 
hence prevent obesity 
[26] 
.Another protective mechanism in
obesity is the brown adipose tissue (BAT) action by 
thermogenesis, with uncoupling proteins (UCPs) active 
expression when fatty acid concentrations are high. Thus, 
there is the homeostasis restoration and promotion of 
protective mechanism against the increased lipid metabolism 
and fat storage. So, this favors an increase in energy 
expenditure and WAT reduction, besides modulates the body 
composition and, therefore, prevents the obesity and 
disorders related to such disease 
[27-29]
. In this way, in a study
proposed by Ye 
[30]
, the IL-15 administration increased the
UCPs expression, promoting thermogenesis – one of the 
mechanisms which induces energy expenditure, and 




IFN-γ is a cytokine produced by T and natural killer cells 
(NK). It has pro-inflammatory effects in the immune system 
and also in adipose tissue and is able to increase the ability of 
macrophages and endothelial cells to present antigens and 
stimulate the production of other inflammatory mediators, 
such as: Tumor Necrosis Factor-Alpha (TNF-α) and 
interleukin-1 (IL-1), which amplify the inflammation 
[10, 32]
.
In a study proposed by Khazen et al. 
[33]
 both in rodents
and in humans, the IFN-γ presence had a particular effect in 
adipocytes leading to a rapid and extensive decline in 
phosphoenolpyruvate carboxykinase expression (PEPCK) in 
glyceroneogenesis, increasing the release of plasma free fatty 
acids, which could be involved in insulin resistance induced 
by obesity. Waite et al. 
[34]
 proposed another mechanism, in
which IFN-γ inhibited the peroxisome proliferator-activated 
receptor (PPAR) expression in adipocytes and, consequently, 
decreased the lipoprotein Lipase (LPL) activity, resulting in 
the development of insulin resistance and lipolysis increase. 
Recent studies have shown that high IFN- γ concentrations 
increase in obesity in models, humans and rodents, while its 
deficiency results in a better glucose tolerance in rats. 
Precisely because the IFN-γ is high in obesity, studies 
suggest that this cytokine impairs glucose homeostasis and 
body weight control 
[8-10]
.
According to Rocha et al. 
[9]
 the messenger Ribonucleic
Acid (mRNA) expression to IFN-γ in adipose tissue is higher 
in obese than control animals. Interestingly, the T cells, 
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extracted from obese rats adipose tissue and stimulated in 
vitro also produce IFN-γ higher quantity than that extracted 
from lean animals 
[9]
.
In other hand, the IFN-γ suppression in rats resulted in a 
body weight reduction associated with food intake reduction 
and voluntary physical activity increase. Consequently, the 
glucose homeostasis improved due to insulin sensitivity 
increase, associated with glyconeogenesis reduced activity by 
decrease in glucose-6-phosphate expression. In relation to 
food intake reduction, the mRNA expression of neuropeptide 
Y (NPY) - the hunger stimulating neuropeptide - reduced 
significantly, whereas the hunger suppression neuropeptide, 
the Pro-opiomelanocortin (POMC) increased significantly. 
Moreover, it was also observed a significant increase in 
plasma leptin, which is proportional to adiposity. It is well 
established that the leptin modulates the action of central 
neuropeptides, NPY and POMC, in order to reduce the food 
intake and increase the energy expenditure. So, the IFN-γ 
suppression plays an essential role in energy balance, 




IL-15 is produced by monocytes/ macrophages in 
immunology system and its genes were also detected in 
placenta, skeletal muscle, kidney, lung and heart 
[35-38]
. Such
cytokine exerts anti-inflammatory action on adipose tissue, 
playing pleiotropic functions, by apoptosis stimulation and its 
capacity to modulate the metabolism, and pro-inflammatory 
function since it promotes the IFN- γ expression, which 
amplifies the inflammation. The IL-15 mRNA is highly 
expressed in skeletal muscle tissue, thus it has a greater 
function as an endocrine factor, which may be associated 




It is believed that IL-15 has the ability to modulate the 
body composition by exerts direct effects on the 
carbohydrates and lipids metabolism, as well as on the 
insulin sensitivity fatty acid oxidation, lipogenesis inhibition, 
very low density lipoprotein decrease (VLDL) and 
thermogenesis promotion [30, 35, 37, 40, 41]. 
For such efects, IL-15 increases the glucose capitation 
striated muscle, since it enhances the GLUT4 expression in 
muscle cells, improving the insulin sensitivity both in vitro 
and in vivo. The IL-15 administration resulted in increase of 2- 
deoxyglucose capitation by skeletal muscle 
[35, 40]
. Besides
promoting changes in carbohydrates oxidation, IL-15 also 
seems to influence the fatty acid oxidation in skeletal muscle. 
As the study in experimental animals by oral administration of 
exogenous triglycerides showed the IL-15 treatment increases 
the fatty acid oxidation in skeletal muscle 
 [37]
.
Furthermore, with in vivo effect, a study showed that 
IL-15 chronic administration (seven days) resulted in a BAT 
reduction of 33% in healthy rats. Additional studies show 
that this cytokine effects on BAT are partly caused by the 
lipogenesis inhibition, through lipoprotein lipase (LPL) 
activity and by reducing the fat absorption in this tissue. 
IL-15 also regulates the lipogenesis in liver, because it 
modulates the hepatic citrate concentrations, one of the major 
activators of acetyl-CoA carboxylase – a regulating lipogenic 
pathway enzyme. The lipogenesis reduction was 
accompanied by an increase in fatty acid oxidation, because 
it increased the carnitine palmitoyltransferase 1 (CPT1) and 
carnitine palmitoyltransferase 2 (CPT2) levels in liver. The 
results of these IL-15 alterations in lipid metabolism in liver 
is possibly a reduction in triacylglycerol’s exportation in 
VLDL form, reducing the lipid content by VLDL particles 
[37]
. Moreover, in rats, IL-15 administration promoted
thermogenesis in BAT, due to better UCP-1 and UCP-3 
expressions. In this study, the IL-15 treatment decreased 
WAT and BAT (35% and 24%, respectively). So, IL-15 can 
induce the BAT energy expenditure, through thermogenesis, 




According to Barra et al. 
[42]
 obese individuals have 
smaller IL-15 concentrations than eutrophic individuals. 
Thus, the IL-15 treatment reduced the body weight in an 
obese animal model induced by diet. The IL-15 effect in vivo 
did not influence the food intake, because IL-15 reduced the 
obesity by means of a mechanism dependent on the leptin 
receptor. Its administration was studied in two genetic 
obesity models: rodents with leptin receptor knockdown and 
rats with leptin deficiency. The IL-15 infusion reduced the 
adiposity in rats with leptin receptor knockdown and those 
which have leptin receptor presented no changes in food 
intake pattern. The author concluded that IL-15 reduces 




In a clinical study, in which body mass index (BMI) was 
evaluated, it was observed negative associations between 
IL-15 plasma concentrations and BMI, total body fat and 
trucal fat 
[43]
. Therefore, these results suggest that IL-15 can




It is worth noting that, so ever IL-15 has beneficial effects 
in the energy metabolism modulation, the inhibition of its 
expression in obesity process is more satisfactory, precisely 
because Il-15 higher concentrations favor the IFN-γ 
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expression and to contribute to amplification of 
inflammatory process, bringing numerous endocrine and 
metabolic consequences. 
IL-4 
IL-4 is produced by CD4 + T lymphocytes, mast cells and 
activated basophils. In addition, it performs pleiotropic 
functions, such as: the induction of Th2 differentiation, shift 
in immunoglobulin class and proliferation of B cells in the 
immune system. Besides the immune system, IL-4 is present, 
constitutively, in different parts of the body, such as: the 
kidney, spleen, liver, brain, skeletal muscle, heart and adipose 
tissue. In the latter, it plays anti-inflammatory action, 
limiting the characteristic subclinical inflammation of obesity 
[6]
.
According to the studies proposed in the literature, IL-4 
when expressed by adipocytes and hepatocytes shows the 
ability to modulate local immune responses, besides being 
associated with the increased insulin sensitivity and glucose 
tolerance. This inhibits the lipids accumulation in adipose 
tissue, resulting in decreased weight gain and body fat [6,
11-14].
Thus, in a recent study proposed by Tsao et al. 
[6]
 the IL-4
presence in the adipocyte differentiation process resulted in 
the inhibition of 30% of lipid accumulation in differentiated 
cells due to decreased and delayed in the expression of 
important genes, which mediate adipogenesis, PPAR and the 
CCAAT/enhancer binding proteins (C/EBP). Moreover, IL-4 
has demonstrated inhibitory effects of genes involved in 
glucose uptake and lipid metabolism, such as: GLUT4 and 
LPL. Therefore, beyond inhibiting adipocyte differentiation 
through the STAT6 pathway, it enhances lipolysis by 
increasing levels of cyclic adenosine monophosphate (cAMP). 
The cAMP activates the protein kinase A (PKA), followed by 
phosphorylation of hormone-sensitive lipase (HSL), 
mediating the triacylglycerol’s hydrolysis. Thus, IL-4 
participates of the lipid metabolism evoking a conventional 
lipolytic pathway. In addition to these results, it was also 
found that IL-4 modulates the resistin expression (hormone 
involved in lipolysis promoting, glucose and insulin 
intolerances) inhibiting the lipid accumulation in adipose 
tissue, which consequently leads to the reduction of the body 
weight gain. Given these scientific evidences about the IL-4 
role in adipose tissue, it is suggested that this cytokine is 
inversely proportional to weight gain and adiposity.  
According to the aforementioned study, Gonzalez et al. 
[13] 
also found that IL-4 treatment in rat hepatocytes increased 
the STAT6 phosphorylation, suggesting its involvement in 
hepatic metabolism. Thus, IL-4 suppressed the β-oxidation of 
fatty acids in 50% and increased the hepatic glucose 
oxidation in 450%. However, when it was administered in 
rats with STAT6 deficiency, it had an opposite effect; 
shifting the glucose metabolic dependence for fatty acid 
oxidation in hepatocytes. This change was accompanied by 
an increased activity of alpha receptors activated by PPAR, 
key regulator of the β-oxidation in liver pathways. In 
addition, the experiment when challenged with a high fat diet, 
STAT6 null rats gained significantly less weight and had 
small WAT deposits, totaling a 60% reduction in body fat 
mass and 43% in adiposity. This difference in weight gain 
and adiposity was not caused by loss of adipogenesis, but by 
the food intake decrease, which implies that the STAT6 null 
rat’s resistance in induced obesity by high fat diet results 
from the increased energy expenditure.  
Besides the function of decreasing the adipogenesis and 
favoring the reduction of adipose tissue, the IL-4 is also 
known as the trigger signal for the phosphorylation of the 
substrates and insulin receptors. This suggests that it may be 
positively associated with the regulation of insulin signaling 
pathways. In vivo effects of IL-4 overexpression promoted 
changes in the protein kinase B activity (PKB) and glycogen 
synthase Kinase 3β (GSK3β) of the rats muscle cells, 
suggesting that it may result in improved glucose tolerance, 





IL-13, a cytokine produced by T and B cells, mast cells, 
basophils, NK and dendritic cells, plays a key role in 
inflammation and immune responses [44]. 
In adipose tissue, a recent study proposed by Kwon et al. 
[45]
demonstrated that in both rats and humans there is an
increase in inflammatory markers and also a marked increase
in IL-13 production. These data suggest that IL-13
expression in adipose tissue is increased. A high fat diet
induced signs of pro-inflammatory cytokines originating
from adipose tissue by immune cells activation, the kinase
complex (IKK), which also releases IL-13. It, in turn, has
paracrine function to suppress the expansion of
pro-inflammatory cells in adipose tissue, in other words, it is
anti-inflammatory. These data show a defense mechanism
present in adipocytes, which limit the inflammation and
insulin resistance by their autoregulation. Thus, it is
conceivable that during an inflammation process, one of the
main functions of IL-13 is restore the glucose homeostasis,




In the study performed by Stanya et al. 
[46]
 in rats, data
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Table 1. Adipokines involved in the modulation of the energy metabolism 
Behavior in obesity Concentrations Effects References 
Antiinflammatory Increased  ↑ Insulin sensitivity 
 ↓ Body fat 
Tsao et al.[6]; El-Wakkad et al.[11]; 
Ricardo-Gonzalez et al.[12];  Damluji et 
al. [13]; Chang et al .[14] 
Antiinflammatory Increased  Restores the glucose homeostasis 
 Limits the inflammation
Zhou et al. [40]; Kwon et al. [41];  Stanya 
et al. [42] 
Antiinflammatory Increased  Inhibits the lipogenesis
 Improves the insulin sensitivity 
 Modulates the energy metabolism 
Febbraio [25]; Sanchez-Jimenez e 
Alvarado-Vasquez et al. [31];  Quinn e 
Anderson [35]; Ye,[36];Barra et al. [37]; 
Fuster et al. [38] 
Pro-inflammatory Decreased  ↑ total body fat
 ↑ truncal fat 
Febbraio [25];  Sanchez-Jimenez e 
Alvarado-Vasquez [31];  Quinn e 
Anderson [35]; Ye [36]; Barra et al. [37]; 
Fuster et al. [38]  
Pro-inflammatory Increased  ↑Insulin resistance 
 ↑Adiposity 
Wong et al. [8]; Rocha et al. [9]; O'rourke 
et al.[10];  Khazen et al.[43] 
Reduced/Suppressed  ↓ Body weight
 Improves the glucose homeostasis 
Wong et al .[8] 
IL: Interleukin; IFN-γ: Interferon-gamma; ↑: increase; ↓decrease. 
showed that depletion of IL-13 gene led to hyperglycemia 
accompanied by a high expression of genes required for 
synthesis of glucose in the liver, insulin resistance, decreased 
oxygen consumption, weight gain and increased triglyceride 
levels in blood and liver, contributing to the development of 
metabolic syndrome. However, its presence suppressed the 
postprandial hyperglycemia. IL-13 is probably necessary 
when the insulin signaling is compromised or suppressed, as 
in the cases of overfeeding, which leads to obesity. It acts as 
a physiological signal that activates the STAT3 pathway to 
suppress hepatic glucose production (gluconeogenesis) by 
inhibiting the genes expression of EPKC and 
glucose-6-phosphatase enzymes. 
In this way, it is concluded that the inflammation present 
in adipose tissue induces the IL-13 expression, which serves 
to maintain a low level of chronic inflammation and, thereby, 
limit the action of pro-inflammatory cytokines and, therefore, 
help to the minimization of the characteristic inflammatory 
and metabolic effects of obesity. 
Finally, the chart below summarizes the action of 
adipokines on the parameters that modulate energy 
metabolism and are also associated with the prevention or 
promotion of obesity (Table 1). 
Final considerations 
Given the aforementioned, scientific evidence 
demonstrates that activation of NF-kB STAT- JNK pathways 
promotes the expression of cytokines with pro and 
anti-inflammatory effects, such as cytokines, IL-4, IL-13, 
IL-15 and IFN -γ, which are associated with altered 
biochemical, anthropometric and body composition 
parameters that modulate energy metabolism and, 
consequently, may predispose or prevent obesity and its 
metabolic changes. 
Although this pathway activation might modulate the 
energy metabolism through the secretion of cytokines with 
anti-inflammatory effect, its blockade would be more 
appropriate since the same route also secretes 
pro-inflammatory cytokines, such as IFN-γ that at high 
concentrations favors the body weight gain and hence 
predisposes obesity. 
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